Health
Neuren Phase 2 trial shows significant improvements in Phelan-McDermid syndrome
Highlights: * Significant improvement was assessed by both clinicians and caregivers across multiple efficacy measures * Improvements were consistently seen across clinically important aspects of Phelan-McDermid syndrome, including communication, behaviour, cognition/learning and socialis...
2023-12-18 19:00
1254
NUS researchers develop an innovative and flexible method to study immune cell capabilities
This simple and efficient method can directly identify and sort immune cells involved in cell-mediated cytotoxicity SINGAPORE, Dec. 17, 2023 /PRNewswire/ -- Our body's immune system is a complex network of organs, cells, and proteins that work in synchrony to protect our bodies against infection...
2023-12-18 14:47
1499
GC Biopharma Announces US FDA Approval for ALYGLO™ (Immune Globulin Intravenous, Human-stwk) 10% Liquid for Adults with Primary Humoral Immunodeficiency (PI)
YOGIN, South Korea, Dec. 17, 2023 /PRNewswire/ -- GC Biopharma Corp (006280.KS) today announces that the US Food and Drug Administration (FDA) has approved ALYGLO (immune globulin intravenous, human-stwk) 10% Liquid, formerly referred to as "GC5107," for the treatment of adult patients aged 17...
2023-12-18 09:49
1599
GeneQuantum and BioMap establish a strategic collaboration to jointly develop a series of next-generation ADC therapeutics
SUZHOU, China, Dec. 17, 2023 /PRNewswire/ -- Recently, GeneQuantum Healthcare (GQ), a global leader in ADC new drug development focused on innovative bioconjugation technologies, and BioMap, a global leader in life science AI Foundation protein-centric Large Language Models, announced that the...
2023-12-18 09:43
1430
First Patient Dosed in Clinical Trial of YOLT-201 for the Treatment of Hereditary ATTR-CM
SHANGHAI, Dec. 17, 2023 /PRNewswire/ -- YolTech Therapeutics today announced that the first patient has been dosed with YOLT-201, the company's firstin vivo genome editing candidate being developed as a single dose, potentially curative therapy for hereditary transthyretin amyloidosis with cardio...
2023-12-17 23:15
1627
Caliway Closes Oversubscribed Capital Raise and Secures Over $100M to Advance CBL-514 Pivotal Phase 3 Study in Subcutaneous Fat Reduction
TAIPEI, Dec. 16, 2023 /PRNewswire/ -- Caliway Biopharmaceuticals (Caliway) announced that it has closed an oversubscribed capital raise, securing over$100M by issuing 8 million new shares. The new funding will enable Caliway to advance the clinical development of its lead pipeline CBL-514, a sma...
2023-12-16 15:47
2030
Ubie Won the "Best with AI" in Google Play Best of 2023 (Japan)
NEW YORK, Dec. 15, 2023 /PRNewswire/ -- Ubie, Inc., headquartered at 1460
Broadway,New York, NY 10036 and led by CEO Kota Kubo, proudly announces that
the Japanese version of Ubie's AI Symptom Checker (https://ubie.app/
2023-12-16 00:00
2309
Akeso Published Results from CD47 Antibody Ligufalimab in Combination with Azacitidine for Newly Diagnosed Higher-Risk Myelodysplastic Syndrome and Treatment-naïve Acute Myeloid Leukemia at ASH 2023
HONG KONG, Dec. 15, 2023 /PRNewswire/ -- Akeso published two phase Ib clinical results of its innovative CD47 monoclonal antibody ligufalimab (AK117) in combination with azacitidine in patients with newly diagnosed higher-risk myelodysplastic syndrome (HR-MDS) and treatment-naïve acute myeloid le...
2023-12-15 21:00
1671
SeekIn and OncoInv Collaborate to Expand the Global Accessibility of Multiple Cancer Detection Tests and Bridge Global Disparities in Cancer Care
SeekIn to Grant Oncolnv the Rights to Represent SeekIn's Comprehensive Range of Cancer Detection Tests in Twelve Countries to Provide Individuals with Accessible and Affordable Cancer Detection Tests SHENZHEN, China, Dec. 15, 2023 /PRNewswire/ -- SeekIn Inc, a leader in blood-based cancer early ...
2023-12-15 21:00
1567
Live from ASH 2023 | Oral Report Featuring Encouraging Data of Olverembatinib Combined with Reduced-Intensity Chemotherapy in Patients with Ph+ ALL Presented at the ASH Annual Meeting
SUZHOU, China and ROCKVILLE, Md., Dec. 14, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today thatProf. Xiaoyuan Gong of the Institute of Hemato...
2023-12-15 11:14
1875
Nona Biosciences Enters into a Global License Agreement with Pfizer for HBM9033, an MSLN-Targeted Antibody-Drug Conjugate (ADC)
* Nona Biosciences will receive a total of up to $53 Million in upfront and near-term payments, with the potential for milestones of up to$1.05 billion plus royalties. * Pfizer partnership expands Nona's global network of collaborations, reinforcing its commitment to providing cutting-edge te...
2023-12-15 07:30
1720
Lunit to Acquire Volpara: Scheme Implementation Agreement Signed
- Lunit's strategic global leap: to acquire all of Volpara shares at AUD 1.15 per share, envisioning completion by Q2 2024 SEOUL. South Korea, Dec. 14, 2023 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today announced ...
2023-12-14 22:05
1536
China Jo-Jo Drugstores Granted A Second Extension to Meet Nasdaq Minimum Bid Price Requirement
HANGZHOU, China, Dec. 14, 2023 /PRNewswire/ -- China Jo-Jo Drugstores, Inc. (NASDAQ: CJJD) (the "Company"), a leading online and offline retailer and wholesale distributor of pharmaceutical and other healthcare products and healthcare provider inChina, today announced that on December 13, 2023, t...
2023-12-14 21:30
3559
Titans Gather, Future Embarks: The GenScript Biotech Global Forum coinciding with the 2024 J.P. Morgan Healthcare Conference in San Francisco to Convene 20+ KOLs, Exploring Disruptive Transformations and Infinite Opportunities in GCT
Keynote speaker Peter Marks to Deliver Address Free Early Bird Registration Closing Soon NANJING, China, Dec. 14, 2023 /PRNewswire/ -- Technological advancements continuously empower the life sciences. Gene and cell therapy (GCT), as breakthrough treatments, are turning the once-unreachable dre...
2023-12-14 20:34
2457
Fosun Pharma's Global Multi-Center Phase III Clinical Trial Project for A New Antimalarial Drug Receives 500 Million Japanese Yen Investment from GHIT Fund to Jointly Improve the Global Accessibility of Antimalarial Drugs
SHANGHAI, Dec. 14, 2023 /PRNewswire/ -- The Japan-based Global Health Innovative Technology Fund (GHIT Fund) announced today that it will invest approximatelyUS$3.3 million (approximately 500 million yen[1]) in a global multicenter Phase III clinical trial project (the "Program") led by Fosun Ph...
2023-12-14 17:00
3870
Abbisko Therapeutics Announces that U.S. FDA Has Granted Fast Track Designation for Its CSF-1R Inhibitor Pimicotinib (ABSK021)
SHANGHAI, Dec. 13, 2023 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics") today announced that its CSF-1R inhibitor pimicotinib (ABSK021) has been granted the fast track designation ("FTD") by the U.S. FDA for the treatment of tenosynovial giant cell tumor ("TGCT") patients ...
2023-12-14 08:30
1678
WAT Medical Joins World's Largest Boat Show
VANCOUVER, BC, Dec. 13, 2023 /PRNewswire/ -- Discover Boating Miami International Boat Show (DBMIBS) is the world's largest boat and yacht show. The convention, which attracts over 100,000 visitors from more than 35 countries, provides an opportunity for aquatic innovations and consumer products...
2023-12-13 22:00
1582
Virtual twin to improve treatment with cancer immunotherapies
COLOGNE, Germany, Dec. 13, 2023 /PRNewswire/ -- An international team started the research project CERTAINTY inDecember 2023. Together with partners from science, industry and the healthcare sector, the project team led by the Fraunhofer Institute for Cell Therapy and Immunology IZI aims to devel...
2023-12-13 21:06
1388
Alebund Reports Update for AP306 (EOS789), a First-in-Class Pan-inhibitor of Sodium-dependent Phosphate Transporters, from a Completed Phase II Clinical Trial in Patients with Hyperphosphatemia on Hemodialysis
SHANGHAI, Dec. 13, 2023 /PRNewswire/ -- Alebund Pharmaceuticals
2023-12-13 21:00
1617
Dizal's Sunvozertinib Pivotal Study Results Published in The Lancet Respiratory Medicine
SHANGHAI, Dec. 13, 2023 /PRNewswire/ -- Dizal today announced that the results of a phase 2 pivotal study of sunvozertinib for the treatment of platinum-pretreated non-small-cell lung cancer (NSCLC) patients with EGFR exon 20 insertion mutations (exon20ins) (WU-KONG6) were published in the peer-...
2023-12-13 18:00
1662
Week's Top Stories
Most Reposted
Brankas Launches Integrated APAC Open Banking Compliance Solution with ADVANCE.AI's eKYC Solution
[Picked up by 319 media titles]
2024-11-07 09:00
Going Global: DCITS Embarks on International Expansion at Singapore Fintech Festival
[Picked up by 313 media titles]
2024-11-12 09:00
DKSH Healthcare and Euris Unveil CRM & MCE Platform "ConnectPlus" to Revolutionize APAC Healthcare Distribution
[Picked up by 290 media titles]
2024-11-13 09:00
Sobot Introduces its All-in-One Solution at GITEX Global 2024
[Picked up by 289 media titles]
2024-11-12 11:00
Ubiqconn Technology to Showcase Latest Marine Solutions at the 2024 International WorkBoat Show in New Orleans
[Picked up by 289 media titles]
2024-11-11 21:00
Most Read
Brankas Launches Integrated APAC Open Banking Compliance Solution with ADVANCE.AI's eKYC Solution
2024-11-07 09:00
10141
XtalPi and Sinar Mas Multiartha Launch Strategic Partnership to Revolutionize AI Across Asia-Pacific
2024-11-07 11:34
7500
XTEP's First Mono Store in Malaysia Comes to Puchong
2024-11-07 10:08
6214
